{"id":56804,"date":"2026-02-10T23:36:09","date_gmt":"2026-02-10T15:36:09","guid":{"rendered":"https:\/\/flcube.com\/?p=56804"},"modified":"2026-02-10T23:36:10","modified_gmt":"2026-02-10T15:36:10","slug":"foresee-pharmaceuticals-licenses-mmp-12-inhibitor-portfolio-to-primevera-for-584-5-million","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56804","title":{"rendered":"Foresee Pharmaceuticals Licenses MMP-12 Inhibitor Portfolio to Primevera for $584.5 Million"},"content":{"rendered":"\n<p><strong>Foresee Pharmaceuticals<\/strong> has entered an <strong>exclusive global licensing agreement<\/strong> with <strong>Primevera Therapeutics<\/strong>, a <strong>German biotech firm<\/strong>, for its <strong>Matrix Metalloproteinase-12 (MMP-12) inhibitor series<\/strong>. The transaction, valued at up to <strong>USD 584.5 million<\/strong>, includes <strong>clinical-stage assets FP-025 (aderamastat)<\/strong> and <strong>FP-020 (linvemastat)<\/strong>, alongside a <strong>third-generation preclinical candidate<\/strong>, positioning Primevera to advance novel <strong>anti-fibrotic and anti-inflammatory therapies<\/strong> for rare immune-fibrotic diseases and respiratory conditions.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-structure\">Transaction Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Foresee Pharmaceuticals (Taiwan\/China-based)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Primevera Therapeutics (Germany)<\/td><\/tr><tr><td><strong>Assets<\/strong><\/td><td>MMP-12 inhibitor portfolio: FP-025, FP-020, third-generation candidate<\/td><\/tr><tr><td><strong>Total Deal Value<\/strong><\/td><td><strong>Up to USD 584.5 million<\/strong><\/td><\/tr><tr><td><strong>Upfront<\/strong><\/td><td>USD 10 million<\/td><\/tr><tr><td><strong>Milestones<\/strong><\/td><td>Up to USD 574.5 million (development, regulatory, commercial)<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Tiered single-digit percentages<\/td><\/tr><tr><td><strong>Equity Component<\/strong><\/td><td>Foresee acquires <strong>19% equity stake<\/strong> in Primevera<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-pipeline-amp-asset-profile\">Clinical Pipeline &amp; Asset Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Asset<\/th><th>Stage<\/th><th>Primary Indication<\/th><th>Strategic Pivot<\/th><\/tr><\/thead><tbody><tr><td><strong>FP-025 (aderamastat)<\/strong><\/td><td>Phase 2 completed<\/td><td>Allergic asthma (historical)<\/td><td><strong>Rare immune-fibrotic diseases<\/strong>: cardiac sarcoidosis lead indication<\/td><\/tr><tr><td><strong>FP-020 (linvemastat)<\/strong><\/td><td>Phase 1 completed<\/td><td>Healthy subjects<\/td><td><strong>Asthma Phase II<\/strong>: US FDA IND submission <strong>early 2026<\/strong><\/td><\/tr><tr><td><strong>Third-gen MMP-12 inhibitor<\/strong><\/td><td>Drug discovery<\/td><td>Undisclosed<\/td><td>Next-generation optimization for selectivity and CNS penetration<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-target-biology-amp-therapeutic-rationale\">Target Biology &amp; Therapeutic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>MMP-12 (Macrophage Metalloelastase):<\/strong><\/li>\n\n\n\n<li><strong>Key driver<\/strong> of tissue remodeling, fibrosis progression, and inflammatory matrix degradation<\/li>\n\n\n\n<li><strong>Overexpressed<\/strong> in idiopathic pulmonary fibrosis, cardiac sarcoidosis, severe asthma, and COPD<\/li>\n\n\n\n<li><strong>Genetic validation:<\/strong> MMP-12 knockout mice demonstrate <strong>resistance to fibrosis and emphysema<\/strong><\/li>\n\n\n\n<li><strong>FP-025 Differentiation:<\/strong><\/li>\n\n\n\n<li><strong>Completed Phase 2 in allergic asthma<\/strong> establishes <strong>clinical safety database<\/strong><\/li>\n\n\n\n<li><strong>Pivot to cardiac sarcoidosis<\/strong> addresses <strong>orphan indication<\/strong> with no approved therapies and <strong>high unmet need<\/strong><\/li>\n\n\n\n<li><strong>Anti-fibrotic mechanism<\/strong> distinct from TGF-\u03b2 inhibitors (pirfenidone, nintedanib)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning-amp-partnership-logic\">Strategic Positioning &amp; Partnership Logic<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Strategic Value<\/th><\/tr><\/thead><tbody><tr><td><strong>Primevera Focus<\/strong><\/td><td>German biotech <strong>specializing in fibrosis and immunology<\/strong>; MMP-12 aligns with pipeline thesis<\/td><\/tr><tr><td><strong>Foresee Equity Stake (19%)<\/strong><\/td><td><strong>Upside participation<\/strong> in Primevera valuation growth; transforms licensing into strategic investment<\/td><\/tr><tr><td><strong>Global Rights Transfer<\/strong><\/td><td>Primevera assumes <strong>development risk and funding<\/strong> for US\/EU regulatory pathways<\/td><\/tr><tr><td><strong>Rare Disease Strategy<\/strong><\/td><td>Cardiac sarcoidosis and orphan fibrotic indications enable <strong>premium pricing and fast-track designations<\/strong><\/td><\/tr><tr><td><strong>Respiratory Retention<\/strong><\/td><td>FP-020 asthma development maintains <strong>MMP-12 validation in larger market<\/strong> alongside rare disease focus<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-roadmap\">Development Roadmap<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Asset<\/th><th>Milestone<\/th><th>Timeline<\/th><\/tr><\/thead><tbody><tr><td><strong>FP-025<\/strong><\/td><td>Cardiac sarcoidosis Phase 2 initiation<\/td><td>2026<\/td><\/tr><tr><td><strong>FP-020<\/strong><\/td><td>FDA IND submission; Phase 2 asthma start<\/td><td><strong>Early 2026<\/strong><\/td><\/tr><tr><td><strong>Third-gen inhibitor<\/strong><\/td><td>Lead optimization and candidate selection<\/td><td>2026-2027<\/td><\/tr><tr><td><strong>Primevera Financing<\/strong><\/td><td>Series A\/B to fund clinical execution<\/td><td>2026 (Foresee participation via 19% stake)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding MMP-12 inhibitor clinical development, Primevera Therapeutics&#8217; financing and execution capabilities, and Foresee Pharmaceuticals&#8217; equity value appreciation. Actual results may differ due to rare disease trial enrollment challenges, competitive dynamics in fibrosis (Boehringer Ingelheim, Roche), and Primevera&#8217;s ability to advance multiple Phase 2 programs simultaneously.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Foresee Pharmaceuticals has entered an exclusive global licensing agreement with Primevera Therapeutics, a German biotech&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1895,4603],"class_list":["post-56804","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-foreseen-biotechnology","tag-primevera-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Foresee Pharmaceuticals Licenses MMP-12 Inhibitor Portfolio to Primevera for $584.5 Million - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Foresee Pharmaceuticals has entered an exclusive global licensing agreement with Primevera Therapeutics, a German biotech firm, for its Matrix Metalloproteinase-12 (MMP-12) inhibitor series. The transaction, valued at up to USD 584.5 million, includes clinical-stage assets FP-025 (aderamastat) and FP-020 (linvemastat), alongside a third-generation preclinical candidate, positioning Primevera to advance novel anti-fibrotic and anti-inflammatory therapies for rare immune-fibrotic diseases and respiratory conditions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56804\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Foresee Pharmaceuticals Licenses MMP-12 Inhibitor Portfolio to Primevera for $584.5 Million\" \/>\n<meta property=\"og:description\" content=\"Foresee Pharmaceuticals has entered an exclusive global licensing agreement with Primevera Therapeutics, a German biotech firm, for its Matrix Metalloproteinase-12 (MMP-12) inhibitor series. The transaction, valued at up to USD 584.5 million, includes clinical-stage assets FP-025 (aderamastat) and FP-020 (linvemastat), alongside a third-generation preclinical candidate, positioning Primevera to advance novel anti-fibrotic and anti-inflammatory therapies for rare immune-fibrotic diseases and respiratory conditions.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56804\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-10T15:36:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-10T15:36:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56804#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56804\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Foresee Pharmaceuticals Licenses MMP-12 Inhibitor Portfolio to Primevera for $584.5 Million\",\"datePublished\":\"2026-02-10T15:36:09+00:00\",\"dateModified\":\"2026-02-10T15:36:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56804\"},\"wordCount\":425,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Foreseen Biotechnology\",\"Primevera Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56804#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56804\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56804\",\"name\":\"Foresee Pharmaceuticals Licenses MMP-12 Inhibitor Portfolio to Primevera for $584.5 Million - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-10T15:36:09+00:00\",\"dateModified\":\"2026-02-10T15:36:10+00:00\",\"description\":\"Foresee Pharmaceuticals has entered an exclusive global licensing agreement with Primevera Therapeutics, a German biotech firm, for its Matrix Metalloproteinase-12 (MMP-12) inhibitor series. The transaction, valued at up to USD 584.5 million, includes clinical-stage assets FP-025 (aderamastat) and FP-020 (linvemastat), alongside a third-generation preclinical candidate, positioning Primevera to advance novel anti-fibrotic and anti-inflammatory therapies for rare immune-fibrotic diseases and respiratory conditions.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56804#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56804\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56804#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Foresee Pharmaceuticals Licenses MMP-12 Inhibitor Portfolio to Primevera for $584.5 Million\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Foresee Pharmaceuticals Licenses MMP-12 Inhibitor Portfolio to Primevera for $584.5 Million - Insight, China&#039;s Pharmaceutical Industry","description":"Foresee Pharmaceuticals has entered an exclusive global licensing agreement with Primevera Therapeutics, a German biotech firm, for its Matrix Metalloproteinase-12 (MMP-12) inhibitor series. The transaction, valued at up to USD 584.5 million, includes clinical-stage assets FP-025 (aderamastat) and FP-020 (linvemastat), alongside a third-generation preclinical candidate, positioning Primevera to advance novel anti-fibrotic and anti-inflammatory therapies for rare immune-fibrotic diseases and respiratory conditions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56804","og_locale":"en_US","og_type":"article","og_title":"Foresee Pharmaceuticals Licenses MMP-12 Inhibitor Portfolio to Primevera for $584.5 Million","og_description":"Foresee Pharmaceuticals has entered an exclusive global licensing agreement with Primevera Therapeutics, a German biotech firm, for its Matrix Metalloproteinase-12 (MMP-12) inhibitor series. The transaction, valued at up to USD 584.5 million, includes clinical-stage assets FP-025 (aderamastat) and FP-020 (linvemastat), alongside a third-generation preclinical candidate, positioning Primevera to advance novel anti-fibrotic and anti-inflammatory therapies for rare immune-fibrotic diseases and respiratory conditions.","og_url":"https:\/\/flcube.com\/?p=56804","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-10T15:36:09+00:00","article_modified_time":"2026-02-10T15:36:10+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56804#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56804"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Foresee Pharmaceuticals Licenses MMP-12 Inhibitor Portfolio to Primevera for $584.5 Million","datePublished":"2026-02-10T15:36:09+00:00","dateModified":"2026-02-10T15:36:10+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56804"},"wordCount":425,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Foreseen Biotechnology","Primevera Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56804#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56804","url":"https:\/\/flcube.com\/?p=56804","name":"Foresee Pharmaceuticals Licenses MMP-12 Inhibitor Portfolio to Primevera for $584.5 Million - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-10T15:36:09+00:00","dateModified":"2026-02-10T15:36:10+00:00","description":"Foresee Pharmaceuticals has entered an exclusive global licensing agreement with Primevera Therapeutics, a German biotech firm, for its Matrix Metalloproteinase-12 (MMP-12) inhibitor series. The transaction, valued at up to USD 584.5 million, includes clinical-stage assets FP-025 (aderamastat) and FP-020 (linvemastat), alongside a third-generation preclinical candidate, positioning Primevera to advance novel anti-fibrotic and anti-inflammatory therapies for rare immune-fibrotic diseases and respiratory conditions.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56804#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56804"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56804#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Foresee Pharmaceuticals Licenses MMP-12 Inhibitor Portfolio to Primevera for $584.5 Million"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56804","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56804"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56804\/revisions"}],"predecessor-version":[{"id":56805,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56804\/revisions\/56805"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56804"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56804"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56804"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}